675 McDonnell Boulevard
About Mallinckrodt PharmaceuticalsMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs.
Founder: Emil Mallinckrodt
CEO: Mark Trudeau
CFO: Matthew Harbaugh
Please click here for Mallinckrodt job opportunities.
316 articles with Mallinckrodt Pharmaceuticals
A conference call for investors will begin at 8:30 a.m. Eastern Time.
10/3/2019Companies from across the globe share information on their business and pipelines.
Mallinckrodt Announces Positive Top-Line Findings from its Observational Registry Assessing Relapse Recovery in Multiple Sclerosis Relapse Patients Treated with Acthar® Gel (Repository Corticotropin Injection)
An analysis of 148 patients enrolled in the registry showed patients treated with Acthar Gel reported significant improvements in their MS relapse symptoms at 2 months
Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit
Mallinckrodt plc announced that it has executed a definitive settlement agreement and release with Cuyahoga and Summit Counties in Ohio in connection with lawsuits pending in multidistrict opioid litigation (MDL) in the U.S. District Court for the Northern District of Ohio
Silence Therapeutics, PLC announces the triggering of the first $2 million in research milestones for SLN500 under the collaboration with Mallinckrodt Pharmaceuticals, a global biopharmaceutical company.
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced positive top-line results from its pivotal Phase 3 clinical trial of its investigational StrataGraft® regenerative tissue.
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the InterContinental New York Barclay, 111 E. 48th St., New York on Wednesday, Oct. 2, 2019.
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse
Retrospective Findings Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and 24th Annual Conference of Rehabilitation in Multiple Sclerosis
Mallinckrodt plc announced it has entered into a definitive agreement to sell its wholly owned subsidiary BioVectra Inc.
Shares of Mallinckrodt are down more than 45% in premarket trading after multiple reports indicate the company plans a restructuring in the wake of the opioid crisis that has promoted a number of lawsuits that implicate the company for its sales practices in the United States.
Mallinckrodt Announces Completion of Previously Disclosed Settlement Agreement with U.S. Department of Justice on Legacy Questcor Sales and Marketing Activities
Mallinckrodt plc reported the company has finalized a previously disclosed agreement with the U.S. Department of Justice to resolve a civil False Claims Act investigation of Questcor's legacy sales and marketing activities first filed in 2012.
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Tuesday, Sept. 10, 2019, at the Morgan Stanley 17th Annual Global Healthcare Conference at the Grand Hyatt, 109 E. 42nd St., New York.
8/19/2019As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Mallinckrodt plc announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1.
8/15/2019Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1.
Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns
Mallinckrodt plc announced publication of results of its Phase 1b clinical trial of StrataGraft®, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)
Trial is to Assess Pharmacokinetics, Pharmacodynamics and Safety of the Oral Administration of MNK-6106 in Patients with HE
Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off
Mallinckrodt plc, a global biopharmaceutical company, reported results for the three months ended June 28, 2019.
8/6/2019Mallinckrodt said it remains committed to becoming an “innovation-driven specialty brands business.”
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Thursday, Sept. 5, 2019, at the Wells Fargo Securities 2019 Healthcare Conference at the Westin Copley Place, 10 Huntington Ave., Boston.